Market Cap 53.17M
Revenue (ttm) 0.00
Net Income (ttm) -8.88M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 516,000
Avg Vol 599,370
Day's Range N/A - N/A
Shares Out 35.21M
Stochastic %K 27%
Beta -3.80
Analysts Strong Sell
Price Target $12.75

Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS...

Industry: Biotechnology
Sector: Healthcare
Phone: 410 297 7793
Address:
115 Pullman Crossing Road, Suite 103, Grasonville, United States
TeaBaggerVance
TeaBaggerVance Mar. 21 at 2:25 PM
$OSTX is entering a convergence window where technical structure and fundamental catalysts are aligning. The daily chart continues to show higher lows with tight consolidation near resistance, indicating sustained accumulation rather than distribution. Volume has remained controlled, suggesting limited dilution pressure while supply is being absorbed. The anticipated BLA clinical module submission represents a key inflection point. With prior modules already submitted and the Type B pre-BLA meeting expected to follow, regulatory visibility is increasing. The FDA’s prior feedback signaling acceptance of biomarker strategy and the requirement for a confirmatory study—already funded and planned—reduces a major overhang. Setups like this—compression into resistance ahead of binary/regulatory catalysts—often precede repricing events as uncertainty compresses. If execution continues, this week may mark the transition from speculative positioning to fundamental revaluation. 📈📈📈
0 · Reply
Eagley3k
Eagley3k Mar. 21 at 6:26 AM
$OSTX about to go.........
1 · Reply
Liogical
Liogical Mar. 20 at 9:28 PM
$OSTX wow holding strong in this shit day!
0 · Reply
Doccjc62
Doccjc62 Mar. 20 at 7:54 PM
$OSTX Lots of upcoming catalysts. Green on an overall very red market day,,,, investors know what's coming
0 · Reply
Juhanialainen
Juhanialainen Mar. 20 at 4:22 PM
$OSTX We are ready to launch!
0 · Reply
BOUDIN420
BOUDIN420 Mar. 20 at 2:46 PM
$OSTX they are borrowing to keep this one down. I will stay patient and keep soaking...
0 · Reply
BearishCandle
BearishCandle Mar. 20 at 3:12 AM
1 · Reply
Eagley3k
Eagley3k Mar. 20 at 1:49 AM
$OSTX If you are smart and i know you are, you should be grabbing all you can here. Why? Simply because the minute they annonce FDA ACCEPTANCE of BLA in April, this means there is a potential PRV worth $200M in the game now. Last i checked the MC as of 3/20/2026 is $53M. That is only the beginning. Here is whats next - EU/UK submission q2 26 - ph1b data of OST- 504 targeting catration resistant prostate cancer q2 26 - OSAH IPO (big deal) spin off 1H 26 - potential Approval for OST-HER2 USA q3 26 - potential Aproval EU/UK q4 26 Along with other pipeline catalysts Im talking 7X - 10X in the next 6 months and it will only be ~$500M MC then you dig?
0 · Reply
TeaBaggerVance
TeaBaggerVance Mar. 19 at 4:33 PM
$OSTX Here’s a great article that was just posted 🤙 https://www.globenewswire.com/news-release/2026/03/19/3259233/0/en/The-Patent-Cliff-is-Coming-Driving-Smart-Money-Towards-Precision-Oncology.html?_gl=1*45pssp*_up*MQ..*_ga*MjEwMDY3MjIwMC4xNzczOTM3OTE4*_ga_B6167QB2TF*czE3NzM5Mzc5MTgkbzEkZzAkdDE3NzM5Mzc5MTgkajYwJGwwJGgw*_ga_ERWPGTJ5X8*czE3NzM5Mzc5MTgkbzEkZzAkdDE3NzM5Mzc5MTgkajYwJGwwJGgw
1 · Reply
AlejandroDeGante
AlejandroDeGante Mar. 19 at 2:37 PM
$OSTX Bought some more @ 1.45 USD
0 · Reply
Latest News on OSTX
OS Therapies Bone Cancer Trial Data Strengthens FDA Case

Jan 15, 2026, 12:30 PM EST - 2 months ago

OS Therapies Bone Cancer Trial Data Strengthens FDA Case


OS Therapies Enters into Warrant Inducement Agreements

Jan 12, 2026, 8:01 AM EST - 2 months ago

OS Therapies Enters into Warrant Inducement Agreements


OS Therapies Provides First Half 2026 Corporate Outlook

Jan 5, 2026, 7:40 AM EST - 2 months ago

OS Therapies Provides First Half 2026 Corporate Outlook


OS Therapies to Participate in Fall 2025 Conferences and Events

Oct 7, 2025, 11:50 AM EDT - 5 months ago

OS Therapies to Participate in Fall 2025 Conferences and Events


OS Therapies Terminates Equity Line of Credit

Aug 25, 2025, 9:51 PM EDT - 7 months ago

OS Therapies Terminates Equity Line of Credit


OS Therapies Provides Clinical & Global Regulatory Updates

Jul 10, 2025, 7:40 AM EDT - 9 months ago

OS Therapies Provides Clinical & Global Regulatory Updates


OS Therapies FDA Meeting Request Granted

Apr 22, 2025, 7:40 AM EDT - 11 months ago

OS Therapies FDA Meeting Request Granted


TeaBaggerVance
TeaBaggerVance Mar. 21 at 2:25 PM
$OSTX is entering a convergence window where technical structure and fundamental catalysts are aligning. The daily chart continues to show higher lows with tight consolidation near resistance, indicating sustained accumulation rather than distribution. Volume has remained controlled, suggesting limited dilution pressure while supply is being absorbed. The anticipated BLA clinical module submission represents a key inflection point. With prior modules already submitted and the Type B pre-BLA meeting expected to follow, regulatory visibility is increasing. The FDA’s prior feedback signaling acceptance of biomarker strategy and the requirement for a confirmatory study—already funded and planned—reduces a major overhang. Setups like this—compression into resistance ahead of binary/regulatory catalysts—often precede repricing events as uncertainty compresses. If execution continues, this week may mark the transition from speculative positioning to fundamental revaluation. 📈📈📈
0 · Reply
Eagley3k
Eagley3k Mar. 21 at 6:26 AM
$OSTX about to go.........
1 · Reply
Liogical
Liogical Mar. 20 at 9:28 PM
$OSTX wow holding strong in this shit day!
0 · Reply
Doccjc62
Doccjc62 Mar. 20 at 7:54 PM
$OSTX Lots of upcoming catalysts. Green on an overall very red market day,,,, investors know what's coming
0 · Reply
Juhanialainen
Juhanialainen Mar. 20 at 4:22 PM
$OSTX We are ready to launch!
0 · Reply
BOUDIN420
BOUDIN420 Mar. 20 at 2:46 PM
$OSTX they are borrowing to keep this one down. I will stay patient and keep soaking...
0 · Reply
BearishCandle
BearishCandle Mar. 20 at 3:12 AM
1 · Reply
Eagley3k
Eagley3k Mar. 20 at 1:49 AM
$OSTX If you are smart and i know you are, you should be grabbing all you can here. Why? Simply because the minute they annonce FDA ACCEPTANCE of BLA in April, this means there is a potential PRV worth $200M in the game now. Last i checked the MC as of 3/20/2026 is $53M. That is only the beginning. Here is whats next - EU/UK submission q2 26 - ph1b data of OST- 504 targeting catration resistant prostate cancer q2 26 - OSAH IPO (big deal) spin off 1H 26 - potential Approval for OST-HER2 USA q3 26 - potential Aproval EU/UK q4 26 Along with other pipeline catalysts Im talking 7X - 10X in the next 6 months and it will only be ~$500M MC then you dig?
0 · Reply
TeaBaggerVance
TeaBaggerVance Mar. 19 at 4:33 PM
$OSTX Here’s a great article that was just posted 🤙 https://www.globenewswire.com/news-release/2026/03/19/3259233/0/en/The-Patent-Cliff-is-Coming-Driving-Smart-Money-Towards-Precision-Oncology.html?_gl=1*45pssp*_up*MQ..*_ga*MjEwMDY3MjIwMC4xNzczOTM3OTE4*_ga_B6167QB2TF*czE3NzM5Mzc5MTgkbzEkZzAkdDE3NzM5Mzc5MTgkajYwJGwwJGgw*_ga_ERWPGTJ5X8*czE3NzM5Mzc5MTgkbzEkZzAkdDE3NzM5Mzc5MTgkajYwJGwwJGgw
1 · Reply
AlejandroDeGante
AlejandroDeGante Mar. 19 at 2:37 PM
$OSTX Bought some more @ 1.45 USD
0 · Reply
Bigbartabs61
Bigbartabs61 Mar. 19 at 2:05 PM
$OSTX Added @1.46
0 · Reply
TeaBaggerVance
TeaBaggerVance Mar. 19 at 12:49 PM
$OSTX This is not a matter of IF it will happen, only a matter of WHEN, and the window for WHEN is shrinking by the minute. 📈📈📈📈📈📈📈📈📈📈📈📈📈📈
0 · Reply
BOUDIN420
BOUDIN420 Mar. 19 at 3:07 AM
0 · Reply
biotrade123
biotrade123 Mar. 18 at 5:54 PM
$OSTX due for an upside, could happen by eow?
1 · Reply
Juhanialainen
Juhanialainen Mar. 18 at 4:15 PM
$SLS Bought some more. $OSTX too.
0 · Reply
Cowboys1
Cowboys1 Mar. 18 at 2:50 PM
$OSTX Part 3 - OS Therapies Announces Filing Form S-1 of OS Animal Health SubsidiaryOS Animal Health (OSAH), a wholly-owned subsidiary of OS Therapies (OSTX), targeting Initial Public Offering (IPO) on NYSE American or Nasdaq Capital Markets national stock exchange in the first half of 2026 (1H/2026) OSTX shareholders expected to receive one (1) share of OSAH for every ten (10) shares of OSTX owned as of the expected to-be-determined 1H/2026 record date
0 · Reply
Cowboys1
Cowboys1 Mar. 18 at 2:45 PM
$OSTX Part 2 - Key Aspects of OSAH (OS Animal Health): Focus: Canine osteosarcoma and HER2-positive cancers. Product: OST-HER2 immunotherapy, aiming for USDA conditional approval. Target Market: Veterinary oncology, specifically targeting pet dogs.
0 · Reply
Cowboys1
Cowboys1 Mar. 18 at 2:44 PM
$OSTX Part 1 - OS Animal Health (OSAH), a subsidiary of OS Therapies, is a company focused on developing and commercializing immunotherapy, specifically OST-HER2, for treating canine osteosarcoma and other HER2-positive cancers in pets, with plans for a 2026 IPO.
0 · Reply
edelhead
edelhead Mar. 18 at 2:13 PM
$OSTX I am wondering if OS Therapies' osteosarcoma treament qualifies for the FDA's new CNPV program. If it does, then look out for something amazing to happen soon!
1 · Reply
biovaluable
biovaluable Mar. 18 at 7:08 AM
$OSTX OSAH is comming!
1 · Reply
TeaBaggerVance
TeaBaggerVance Mar. 17 at 11:25 PM
$OSTX We are setting up for a high-probability move. Clean cup & handle + bull flag + inverse H&S all converging while price holds the $1.44–$1.50 support zone. RSI has reset (~55), MACD remains positive, and volume is contracting into the handle — classic pre-breakout behavior. Key trigger: $1.66–$1.70. Above that, there’s a low-volume pocket to ~$1.85–$2.05, where moves can accelerate quickly. At the same time, near-term regulatory catalysts are approaching, aligning with the exact window where the technical breakout is set to trigger. If volume confirms, OSTX could see a fast expansion phase that could push us very quickly into the mid $2’s. 📈📈📈
0 · Reply
edelhead
edelhead Mar. 17 at 10:32 PM
$OSTX There are a lot of near term catalysts for sure! What I keep thinking about though is - with all of the attention (Congress, the media) now being given to the FDA's recent mishandling of rare disease applications, OS Therapies is in a perfect spot by giving the FDA an opportunity for an important and much needed win (in the area of rare and deadly childhood cancer)! The stars really are aligning for the company, its patients and its shareholders!!
0 · Reply